The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), Johnson & Johnson (Gold), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESH CLL 2026 | Fixed-duration acalabrutinib combinations in CLL
Gianluca Gaidano, MD, PhD, University of Eastern Piedmont, Vercelli, Italy, discusses emerging fixed-duration regimens combining acalabrutinib and venetoclax for chronic lymphocytic leukemia (CLL). He highlights how these strategies challenge the paradigm of indefinite BTK inhibitor therapy while maintaining efficacy and improving tolerability. This interview took place at the ESH CLL 2026 congress in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So the Amplify trial, in fact, have been using acalabrutinib venetoclax versus standard of care and documented the advantage. And that fixed a new paradigm, and that’s the first actually fixed-duration regimen with a second-generation BTK inhibitor. Obviously, we would like to have a head-to-head comparison, which we don’t have yet in the case of acalabrutinim venetoclax. We have it for acalabrutinib venetoclax fixed duration versus acalabrutinib continuous treatment because the CLL17 study documented that clearly, but we don’t have this type of evidence for acalabrutinib as of now...
So the Amplify trial, in fact, have been using acalabrutinib venetoclax versus standard of care and documented the advantage. And that fixed a new paradigm, and that’s the first actually fixed-duration regimen with a second-generation BTK inhibitor. Obviously, we would like to have a head-to-head comparison, which we don’t have yet in the case of acalabrutinim venetoclax. We have it for acalabrutinib venetoclax fixed duration versus acalabrutinib continuous treatment because the CLL17 study documented that clearly, but we don’t have this type of evidence for acalabrutinib as of now. But it’s obviously desirable to have, but in the meantime, I think Acalabrutin venetoclax will be an important and actually already is an important tool for patients. And that allows us to treat patients also a bit older than with IV because it’s safer.
Read more...
